rs121434282 — ACADM Arg281Thr

ACADM Arg281Thr — A Pathogenic MCAD Variant Unmasked by Fasting

Every cell that depends on fat for fuel must first strip two-carbon acetyl groups from fatty acids inside mitochondria, a process called beta-oxidation¹¹ beta-oxidation
The sequential enzymatic removal of acetyl-CoA units from the fatty acid chain, producing NADH and FADH2 for the electron transport chain and feeding acetyl-CoA into the citric acid cycle. The medium-chain step of this pathway — handling fatty acids with 6–12 carbons — is catalysed exclusively by medium-chain acyl-CoA dehydrogenase (MCAD), the protein encoded by ACADM. When MCAD is absent or non-functional, medium-chain fatty acids accumulate, toxic acylcarnitine species build up, and the liver cannot produce enough ketone bodies to spare the brain during fasting. The result — if unrecognised — is hypoketotic hypoglycemia progressing rapidly to seizures, coma, and death.

The c.842G>C variant (rs121434282) exchanges arginine for threonine at position 281 of the MCAD protein (p.Arg281Thr). ClinVar classifies it as Pathogenic (VCV000003596, two-star review status, multiple submitters, no conflicts). It is one of more than 80 pathogenic ACADM variants but one of only three — alongside the common K329E (c.985A>G, rs77931234) and a second minority allele (rs121434281) — that together account for the great majority of disease alleles identified in MCAD deficiency patients.

The Mechanism

Arginine-281 sits within the MCAD active site²² MCAD active site
The catalytic core where FAD (flavin adenine dinucleotide) is positioned to accept electrons from the fatty acid substrate during the dehydrogenation reaction. Arg281 forms critical salt bridges and hydrogen bonds that stabilise the binding of FAD³³ FAD
Flavin adenine dinucleotide — the essential cofactor that shuttles electrons from the fatty acid to the mitochondrial electron transport chain during each oxidation cycle within the enzyme's active site. Replacing arginine (basic, positively charged) with threonine (neutral, hydroxyl-bearing) disrupts the electrostatic network holding FAD in place. The result is an enzyme with severely impaired or absent catalytic activity: medium-chain substrates cannot be oxidised, and the block in fat oxidation becomes clinically apparent whenever carbohydrate reserves are depleted — during overnight fasting, febrile illness, vomiting, or any state that forces the body to switch to fat as its primary fuel.

Because MCAD deficiency is autosomal recessive, a single Arg281Thr allele paired with one normal allele (heterozygous carrier state) leaves one functional MCAD gene copy, which provides sufficient enzyme activity under normal conditions. Two pathogenic alleles — whether homozygous Arg281Thr or compound heterozygous⁴⁴ compound heterozygous
Carrying two different pathogenic alleles of the same gene, one on each chromosome — the most common configuration in MCAD deficiency since K329E is the predominant allele and most affected individuals pair it with a second, rarer variant with another MCAD variant — are required to produce clinical disease.

The Evidence

MCAD deficiency is the most common inherited disorder of mitochondrial fatty acid oxidation. Before universal newborn screening, it carried substantial mortality: a large English screening study⁵⁵ a large English screening study
Oerton J et al. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England: prevalence, predictive value and test validity based on 1.5 million screened babies. J Med Screen, 2011 estimated that up to a quarter of previously undiagnosed children die during their first acute metabolic episode, with a further 16% surviving with severe neurological disability. Prevalence in England is approximately 1 in 10,000 births.

The Arg281Thr variant was first reported by Albers et al.⁶⁶ Albers et al.
Albers S et al. Compound heterozygosity in four asymptomatic siblings with medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis, 2001 in four siblings identified through expanded newborn screening by tandem mass spectrometry. All four were compound heterozygotes — carrying one Arg281Thr allele and one K329E allele — and were asymptomatic at identification despite laboratory confirmation of MCAD deficiency. The authors noted a potentially milder clinical phenotype for this genotype combination and emphasised the importance of cascade testing siblings of any newly screened infant. Despite the milder phenotype observed in this family, ClinVar classifies this variant as pathogenic and clinical management guidelines treat all biallelic ACADM genotypes with the same fasting-avoidance and emergency protocols.

A comprehensive 2023 review by Mason et al.⁷⁷ Mason et al.
Mason E et al. Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment. Endocrinol Diabetes Metab, 2023 confirms that MCAD deficiency prognosis is excellent once diagnosed and managed appropriately, but that acute metabolic decompensation must be treated as a medical emergency requiring immediate glucose administration.

Practical Actions

The cornerstone of MCAD deficiency management is preventing prolonged fasting. Age-based fasting limits are: no more than 3–4 hours for infants, 4–6 hours for toddlers, and up to 8 hours for older children and adults. Every affected individual should carry an emergency letter and medical alert identification explaining their diagnosis and the need for immediate glucose administration during acute illness. L-carnitine supplementation (50–100 mg/kg/day) is commonly prescribed to prevent secondary carnitine depletion from acylcarnitine sequestration, though clinical trials have not definitively demonstrated benefit on outcome endpoints.

Medium-chain triglyceride oils (MCT oil, coconut oil in large amounts) should be avoided because they directly load the blocked pathway with medium-chain fatty acid substrates.

Interactions

The Arg281Thr allele is most commonly observed in trans with the K329E allele (rs77931234), the dominant European MCAD disease allele. This compound heterozygous combination (Arg281Thr/K329E) appeared to confer a milder biochemical phenotype in the originally reported family, though clinical management should follow the same guidelines as classical MCAD deficiency.

Any combination of two pathogenic ACADM alleles — whether Arg281Thr/Arg281Thr, Arg281Thr/K329E, or Arg281Thr paired with rs121434281 or another pathogenic allele — is sufficient to cause MCAD deficiency. The interaction between two biallelic pathogenic variants is the defining genetic event; single-allele carrier status does not cause clinical disease.